Nrf2 signaling in the heart's sympathetic nerves in chronic heart failure

Stellate Ganglia Nrf2 Signaling and Enhanced Cardiac Sympathetic Tone in Chronic Heart Failure

NIH-funded research University of Nebraska Medical Center · NIH-11180508

Testing whether boosting the antioxidant regulator Nrf2 in the nerves that control the heart can calm overactive nerve signals and reduce dangerous heart rhythms in chronic heart failure.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Nebraska Medical Center NIH-funded
Lab location1 site (Omaha, United States)
Project IDNIH-11180508 on NIH RePORTER

What this research studies

This project focuses on the small nerve cluster (stellate ganglia) that sends stress signals to the heart after a heart attack and during chronic heart failure. Researchers will track inflammation, oxidative stress, and the Nrf2 antioxidant regulator over time in that nerve tissue using animal models of post-heart attack heart failure. They will raise or lower Nrf2 in those nerves and measure nerve activity, tissue oxidative damage, and heart rhythm changes to see if boosting Nrf2 calms the nerves. The work aims to point toward ways to prevent nerve-driven dangerous heart rhythms in people with heart failure.

Who could benefit from this research

Good fit: People with chronic heart failure following a heart attack, especially those with signs of high sympathetic activity or recurrent arrhythmias, would be most relevant to this research.

Not a fit: People whose heart failure is due to non-ischemic causes or whose arrhythmias are unrelated to sympathetic nerve overactivity may not directly benefit from these nerve-focused findings.

Why it matters

Potential benefit: If successful, this could point to new treatments that reduce nerve-driven arrhythmias and lower complications after heart attack-related heart failure.

How similar studies have performed: Prior animal studies from these investigators showed that lowering Nrf2 increases nerve activity and raising Nrf2 reduces sympathetic activity and oxidative stress, but applying this approach to prevent post-MI arrhythmias is relatively new.

Where this research is happening

Omaha, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.